Expression levels of interleukin 8 (IL-8), which exhibits significant overexpression in melanoma [18] substantially reduced during BRAF inhibitor treatment [19] and connective tissue growth factor (CTGF), recently considered as a therapeutic target for metastatic melanoma [20], were also significantly reduced by vemurafenib and trametinib in naïve melanoma populations derived from surgical specimens [17]. Here, CCN2 is linked to melanoma.